Abstract-Focused ultrasound with nanodroplets could facilitate localized drug delivery after vaporization with potentially improved in vivo stability, drug payload, and minimal interference outside of the focal zone compared with microbubbles. While the feasibility of blood-brain barrier (BBB) opening using nanodroplets has been previously reported, characterization of the associated delivery has not been achieved. It was hypothesized that the outcome of drug delivery was associated with the droplet sensitivity to acoustic energy, and can be modulated with the boiling point of the liquid core. Therefore, in this study, highly-efficient octafluoropropane (OFP) and less-efficient decafluorobutane (DFB) nanodroplets were used in vivo for delivering molecules with a size relevant to proteins (40-kDa dextran) to the murine brain. It was found that successful delivery was achieved with OFP droplets at 300 kPa or higher safely using ¼ dosage compared to DFB droplets at 900 kPa where inertial cavitation caused damage. As a result, the OFP droplets due to the higher vaporization efficiency served as better acoustic agents to deliver large molecules safely and efficiently to the brain compared with the DFB droplets.
I. INTRODUCTION
The blood-brain barrier (BBB) is a highly selective barrier that blocks most of the therapeutic agents from entering the brain parenchyma, and focused ultrasound (FUS) with microbubbles could open the BBB and facilitate drug delivery [1] . However, the delivery was found to be more contained and thus difficult for larger molecules; i.e., successful and sufficient delivery of large molecules was often accompanied by undesirable tissue damage such as hemorrhage [2] . Moreover, bubble shielding effects (clusters of bubbles in the pre-focal area scattering acoustic waves) caused either the failure of BBB opening [3] or undesired BBB opening in the pre-focal area in large animals [4] . Nanodroplets, as liquid-state phase-change contrast agents, hold great potential to solve these problems after vaporization into microbubbles with sufficient acoustic energy only in the center of focal area [5, 6] , which generates highly concentrated mechanical stress in the targeted vessels. They have been used in therapeutic applications such as BBB opening [7] as well as contrast agents for imaging [8] .
Not only are they characterized by the high echogenicity of conventional microbubble contrast agents post-vaporization, they also exhibit several advantages over bubbles prior to vaporization. First, they may have better in-vivo stability than microbubbles as they are not subject to rapid deflation due to gas diffusion in the bloodstream [9] . Second, the pressure threshold required for vaporization into microbubbles provides a localized delivery method without microbubble interference outside of the focal zone for BBB opening and drug delivery. Third, their capacity to carry high payloads demonstrates significant improvement on targeted treatment and imaging [10] .
The current challenge associated with nanodroplets for brain drug delivery is the low amount of delivery even with small molecules at relatively high pressures compared to using microbubbles. In our first attempt using decafluorobutane (DFB) nanodroplets for drug delivery to the brain, successful BBB opening was achieved with a significantly lower amount of small molecules (3 kDa dextran) delivered compared to using microbubbles [7] . We hypothesized that it was due to a small amount of bubbles generated from DFB droplet vaporization, and that the amount and size of drug delivered was associated with the droplets' sensitivity to acoustic energy. Since the sensitivity or the vaporization efficiency of nanodroplets can be modulated by the boiling point of the perfluorocarbon (PFC) cores [11] , in this study, the drug delivery efficiency was investigated using nanodroplets of different PFC boiling points.
The objective of this study was thus to use low-boilingpoint nanodroplets of different volatility for delivering large molecules to the brain. Lipid-shelled octafluoropropane (OFP, bulk boiling point: −36.7 °C, vaporized at lower pressures) nanodroplets were used in in vivo BBB opening studies in comparison with decafluorobutane (DFB, bulk boiling point: −1.7 °C, vaporized at higher pressures) nanodroplets. In vivo BBB opening with delivery of 40-kDa dextran (size relevant to proteins) was performed in mice, with acoustic signals monitored during sonication in order to reveal the physical mechanism of cavitation associated with the drug delivery after droplet vaporization. The delivery efficiency and safety was assessed with fluorescence microscopy and histological staining, respectively.
II. METHODS

A. Nanodroplet generation
Perfluorocarbon (PFC) droplets containing condensed gases of different boiling points (octafluoropropane or OFP: −36.7 °C, decafluorobutane or DFB: −1.7 °C) (FluoroMed, Round Rock, TX, USA) were fabricated as previously described [11] . Briefly, 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)2000] (DSPE-PEG2000) (Avanti Polar Lipids, Alabaster, AL, USA) were combined at a 9:1 molar ratio and dissolved in a phosphate-buffered saline (PBS)-based excipient solution containing 15% (v/v) propylene glycol and 5% (v/v) glycerol for a final lipid concentration of 1.0 mg/mL. The resultant lipid solution (1.5 mL) was added to 3 mL glass vials, and the headspace air was exchanged with OFP or DFB gas. Microbubbles were formed by vigorous shaking of the lipid-filled vials using a Vialmix mixer (Bristol-Myers-Squibb, New York, NY, USA). The nanodroplets were then generated via microbubble condensation under reduced temperature and increased ambient pressure, as per our previously published protocol [11] .
B. In vivo BBB opening
All animal studies were conducted in accordance with the National Institutes of Health Guidelines for animal research, and all procedures were approved by the Columbia University Institutional Animal Care and Use Committee, and 33 male C57BL/6 mice (Harlan Laboratories, Indianapolis, IN, USA) weighing 20-25 g were used. Before sonication, each mouse was anesthetized using a 1-2% isoflurane-oxygen mixture (SurgiVet; Smiths Medical PM, Norwell, MA, USA) and its scalp fur was removed with an electric clipper and a depilatory cream. A modified 27G×½ butterfly catheter (Terumo Medical, Somerset, NJ, USA) was inserted into the tail vein for injection of the nanodroplets mixed with the fluorescently-tagged dextran (molecular weight: 40-kDa, Stoke-Einstein hydrodynamic diameter: 10 nm, fluorochrome: Texas Red), a model drug with sizes comparable to proteins. The purchased dextran (Life Technologies, Carlsbad, CA, USA) was dissolved to a weight concentration of 40 mg/mL using sterile saline (Fisher Scientific, Pittsburgh, PA, USA), and then 50 μL of the dextran solution was co-administered with either OFP, DFB droplets (25 μL of OFP droplets in cohort 1 or 100 μL of DFB droplets in cohort 2 diluted with 50 μL of sterile saline). Note that the droplet emulsions stored at -80 ºC were thawed at 4 ºC immediately before the injection in order to maintain their stability at low temperature, and the solution appeared to be translucent in contrast to the typical milky microbubble solution.
The experimental setup and procedure are described elsewhere [12] . A single-element, ring-shaped, 1.5 MHz FUS transducer (Imasonic, Besancon, France), calibrated using a hydrophone (-6 dB focal size: 1.3 mm laterally and 10.6 mm axially), and a pulse-echo transducer (center frequency: 10 MHz, focal length: 60 mm; Olympus NDT, Waltham, MA, USA) confocally and coaxially aligned with the FUS transducer were used for both targeting and passive cavitation detection (PCD) purposes.
FUS (excitation frequency: 1.5 MHz, pulse length: 10000 cycles or 6.7 ms, pulse repetition frequency (PRF): 5 Hz, duration: 5 min) at acoustic pressures ranging between 150 and 900 kPa (derated peak-rarefactional pressure after accounting for 18.1% loss through the murine skull [13] ) was applied transcranially to the targeted left hippocampus of the mouse brain while the right hippocampus served as the control without FUS. After the FUS transducer was aligned with the targeted region following a previously published procedure [13] , it was sonicated for 30 s before injecting acoustic agents to serve as a baseline control for PCD. Then the prepared nanodroplet solution was injected as a bolus intravenously followed by 5-min of sonication time initiated within 5 s of the injection. In addition, a sham cohort injected with OFP nanodroplets and dextran without sonication served as the basis for comparison of successful drug delivery in the fluorescence imaging analysis.
A 1-h period was allowed after sonication to enable the fluorescent model drugs to circulate throughout the vasculature and to diffuse into the brain parenchyma. At the end of the allotted time, the animal was sacrificed by transcardial perfusion using 30 mL phosphate buffer saline (PBS) for 5 min followed by 60 mL 4% paraformaldehyde for 8 min through the ventricular catheter connected with an infusion pump, and the blood was pumped out from the pierced right atrium. The mouse brain was extracted from the skull, post-fixed in 4% paraformaldehyde overnight before sectioning for either fluorescence imaging or hematoxylin or eosin (H&E) staining in order to evaluate drug delivery efficiency and safety, respectively.
C. Evaluation of dextran delivery and safety
The fluorescence intensity measurement was performed similarly to our previously reported procedure using Matlab [12, 14] . Briefly, a section representing the ventral-dorsal mid-plane, as determined by anatomical landmarks of the hippocampi, was first selected, and eight adjacent sections were then selected on the ventral and the dorsal side of the mid-plane. The left (sonicated) and the right (unsonicated control) hippocampi were manually delineated using MATLAB (Mathworks Inc., Natick, MA, USA), and the fluorescence intensity increase as well as the BBB opening area were calculated. The fluorescence images for all animals were normalized and thresholded by dividing by the background intensity defined as the spatial average of the intensity of the region without the tissue after adding three times its standard deviation. The area of the BBB opening was calculated as a percentage of the BBB opening area over the unsonicated hippocampi area. The fluorescence intensity increase was the sum of fluorescence intensity in the sonicated hippocampus. For each brain, the reported fluorescence intensity increase was thus equal to the sum of all nine sections. The BBB opening area (intensity > background) denoted a percentage normalized to the size of the hippocampus. For an individual brain, it was considered that a successful dextran delivery was achieved if both the fluorescence intensity increase and the BBB opening area were higher by at least three times the standard deviation relative to the average of the corresponding sham cohort.
The histological examination via hematoxylin and eosin (H&E) staining was performed for safety assessment of both left and right hippocampi 1 h after sonication in cohorts with successful dextran delivery (N=3 in each cohort). The brightfield, stained images were captured by an Olympus DP25 digital camera mounted on the microscope, to identify damaged neurons (dark neurons showing shrunken and triangulated cell bodies) and red blood cell extravasations The area of successful delivery and (E) the fluorescence intensity increase using OFP droplets was linearly correlated with the total stable cavitation dose (SCDu+h = SCDh + SCDu) for the cases with successful delivery. The dash line represents the threshold of successful delivery defined by the sham group (mean plus two times of the standard deviation). Fig. 1 . Delivery efficiency of 40-kDa dextran using fluorescence microscopy after BBB opening. Fluorescence images of sonicated vs. non-sonicated hippocampi (insets) using (A) OFP droplets at 300 kPa, (B) OFP droplets at 450 kPa, (C) DFB droplets at 900 kPa. (D) The average enhanced area due to successful delivery (normalized to the entire hippocampus) and (E) average fluorescence intensity increase for all cohorts, with a dash line representing the threshold of successful delivery defined by the sham group (mean plus 2 time of the standard deviation). Successful delivery was found to be at and above 300 kPa for OFP droplets, and 900 kPa for DFB droplets. Note that OFP represents OFP droplets and DFB for DFB droplets. The scale bar in (A) represents 1 mm.
(hemorrhage). Following the post-fixation process, the brains were paraffin embedded and then sectioned horizontally for safety assessment using a cryostat into 6-μm slices with 180-μm gaps covering the hippocampi. This histological examination was double-blinded, i.e., without knowledge of the droplet type or the sonicated side.
D. Quantification of Cavitation Dose
Three types of cavitation dose (SCD h , stable cavitation dose using harmonics; SCD u , stable cavitation dose using ultraharmonics; ICD, inertial cavitation dose) were quantified [12, 15] . First, the PCD signal of each pulse was converted into the frequency domain using fast Fourier transform in MATLAB (Mathworks Inc., Natick, MA, USA). Second, after taking the root mean square (rms) of the voltage spectral amplitude, the harmonic signal (n*f; n = 3, 4, 5, 6; f = 1.5 MHz; maximum amplitude within a bandwidth of 20 kHz around the harmonic frequency), ultraharmonic signal (n*f+0.5*f; n = 2, 3, 4, 5; f = 1.5 MHz; maximum amplitude within a bandwidth of 20 kHz around the ultraharmonic frequency), and the broadband signal in 3-9 MHz between them (applying a comb filter to suppress the harmonic and ultraharmonic signal with rejection bandwidths of 350 kHz and 100 kHz, respectively) were separately extracted. Third, the mean harmonic, ultraharmonic, and broadband signal were taken for each pulse and summed up over all pulses received during sonication to acquire SCD h , SCD u , and ICD, respectively. Lastly, the differential cavitation doses were computed by subtracting the normalized baseline cavitation doses (10 times the 30s of sonication before microbubble injection). The cavitation doses reported in this study denote the differential cavitation doses.
III. RESULTS
A. Drug delivery efficiency
The in vivo drug delivery using 40-kDa dextran after BBB opening were quantified with fluorescence imaging comparing the fluorescence enhancement in the sonicated hippocampus to the contralateral region (Fig. 1) . With the OFP droplets, successful delivery of 40-kDa dextran was found for 300 kPa (75%, 3 out of 4 mice) (Fig. 1A) and 450 kPa (100%, 5 out of 5 mice) (Fig. 3B ), but not for the 150 kPa group (0 out of 3 mice) which was below the droplet vaporization threshold. For the DFB droplets, successful delivery was found for 900 kPa (100%, 4 out of 4 mice) (Fig.  3C) , whereas no delivery was detected at 750 kPa (0 out of 4 mice). The quantitative results showed similar trend for OFP droplets at 300 kPa to DFB droplets at 900 kPa (p>0.05) in both the area of successful delivery (Fig. 1D ) and the fluorescence intensity increase (Fig. 1E) . Therefore, using OFP droplets we were able to achieve significantly higher delivery at lower pressures with a lower dosage. Notably, sonication at lower pressure with OFP (300 kPa) produced similar results as sonication at a high pressure (900 kPa) using DFB droplets even when a 4 times lower dosage of OFP droplets was used, which corresponded to the in vitro vaporization efficiency measurement.
B. Acoustic cavitation emission
Transcranial cavitation monitoring was performed in all experiments in order to investigate the behavior of cavitation after droplet vaporization associated with drug delivery and safety. The overall cavitation dose representing the cumulative cavitation intensity for each sonication was calculated and shown in Fig. 2 . For the OFP droplets, the SCD h was significantly higher at pressures with successful dextran delivery compared to the control without acoustic agents, showing significant bubble activities occurred after vaporization. Significant SCD u appeared only at the pressure causing the highest amount of delivery (450 kPa), and no significant ICD was found. For DFB droplets, although the SCD h was insignificant due to the low volumetric bubble oscillation at high pressures, the SCD u and the ICD showed statistical significance at 900 kPa with successful delivery compared with the control. Interestingly, although the SCD h for microbubbles was much higher than that for droplets, the SCD u was at the same level or even slightly lower. Since both types of stable cavitation dose were detectable for OFP droplets, their sum (SCD h+u = SCD h + SCD u ) was then plotted against the area of BBB opening (Fig. 2D) as well as Fig. 3 . Safety assessment using histological staining (H&E). Sonicated (A, C, E) and nonsonicated (B, D, F) hippocampi using OFB at 300 kPa (A, B), 450 kPa (C, D), and DFB at 900 kPa (E, F). The results showed no damage (erythrocyte extravasations or dark neurons) using OFP droplets. For DFB droplets at 900 kPa, only 1 out of 3 animals showed an increased amount of dark neurons on the hippocampi. The scale bar in (A) represents 1 mm. the fluorescence intensity increase representing the delivery efficiency (Fig. 1E) . In both of them, good agreement (R 2 = 0.74, 0.92) was found in cases of successful delivery.
C. Safety
Histological (H&E) staining was performed in the cohorts with successful delivery (3 mice from each group: OFP at 300 kPa, OFP at 450 kPa, DFB at 900 kPa) in order to assess any potential tissue damage 1 h after sonication using nanodroplets (Fig. 3) . The results showed no damage, i.e., no red blood cell extravasation or dark neurons using OFP droplets at the pressures leading to successful delivery (Fig. 3A-D) . These results indicate that a safe and effective drug delivery for relatively large molecules could be achieved using OFP droplets. For DFB droplets at 900 kPa, 2 out of 3 animals showed no damage while 1 had more dark neurons in the sonicated hippocampus (Fig. 3E-F) , which corresponded to the statistically significant inertial cavitation detected during sonication (Fig. 2C) .
IV. CONCLUSION
Aiming to enhance drug delivery to the brain, nanodroplets of different boiling points indicating different vaporization efficiencies were used with focused ultrasound to open the BBB for molecular delivery. The findings showed that drug delivery outcomes were directly associated with the volatility of the droplets. Furthermore, the delivery with OFP nanodroplets was safer than with DFB droplets due to the lower vaporization threshold and lower dosage used. Our results constitute the first in vivo demonstration of BBB opening using lower-boiling point OFP nanodroplets for delivering a significant amount of large molecules to the brain, via modulating the vaporization efficiency to improve delivery outcomes.
